Indian stocks: Visit www.stage2stocks.com →

Elutia, Inc. Class A

Stage 4 · Declining · week 10

As of Oct 22, 2026, Elutia is in Stage 4, the downtrend phase, now in week 10 (since Aug 17, 2026). It closed at $0.86, 29.3% below its 52-week high and below its 200-day average, which is rising.

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. More about the company

$0.86
+5.10% today
$38.2M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ELUT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S2 15w
S4 25w
S4 20w
S1 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 14w → S1 6w → S2 13w → S3 9w → S2 15w → S3 3w → S2 3w → S3 4w → S2 7w → S3 2w → S4 25w → S1 7w → S4 20w → S1 14w → S4 1w → S3 12w → S4 10w current
Total tracked: 165 weeks across 17 stage runs.

ELUT among Medical Devices50th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…50ELUTStage 4 · wk 1051−0.7%
vs 52W High
-29.3%
$0.51 lo$1.22 hi
29.3% below 52W high, ongoing decline
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 10
1w13w26w
Week 10, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-11.3%
200 DMA: $0.97 · rising
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.24x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-0.7%
3M
-7.3%
6M
-20.9%
YTD
+34.1%
1Y
-3.8%
Scan Membership
Breakout Watch
Latest: 2024-12-06
6 appearances in last 60 days. First seen: 2022-06-07.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 10 · Vol 0.24x
2026-10-21S4
Wk 10 · Vol 0.36x
2026-10-20S4
Wk 10 · Vol 0.34x
2026-10-19S4
Wk 9 · Vol 0.29x
2026-10-16S4
Wk 9 · Vol 0.41x
2026-10-15S4
Wk 9 · Vol 0.59x
2026-10-14S4
Wk 9 · Vol 1.44x
2026-10-13S4
Wk 9 · Vol 0.18x
2026-10-12S4
Wk 8 · Vol 0.34x
2026-10-09S4
Wk 8 · Vol 0.10x
2026-10-08S4
Wk 8 · Vol 0.56x
2026-10-07S4
Wk 8 · Vol 1.30x
Moving averages & range
50 DMA
$0.84
200 DMA
$0.97
52W High
$1.22
52W Low
$0.51
5D Low
$0.79
Resistance levels (recent highs)
20d High
$0.86
60d High
$1.01
120d High
$1.20
250d High
$1.22
Next resistance
+17.2%
to 60d High
Dividend Yield
0.00%
P/B 2.4

Elutia: quick answers

What stage is Elutia in?

As of Oct 22, 2026, Elutia (ELUT) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 17, 2026 and is in week 10. What the four stages mean

Is Elutia in an uptrend?

No. Elutia is in a Stage 4 downtrend. It trades 11.3% below its 200-day average, which is rising.

How far is Elutia from its 52-week high?

Elutia closed at $0.86 on Oct 22, 2026, 29.3% below its 52-week high of $1.22. Its 52-week low is $0.51.

How has Elutia performed over the past year?

As of Oct 22, 2026, Elutia is down 3.8% over the past year and up 34.1% so far in 2026.

Which sector and industry is Elutia in?

Elutia is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.